CAMP4 Therapeutics Corporation - Common Stock (NQ:CAMP)

CAMP4 Therapeutics (NASDAQ:CAMP) expects initial data from its SYNGAP1 clinical program in the first half of 2028, as the company prepares to begin dosing patients with a treatment designed to increase...

CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears ↗

November 09, 2026

Performance

52-Week Range 44.1% below 52-week high

4.330

2.9052W Low 7.7552W High

1 Week 12.9% below 1-week high

3.541W Low 4.971W High

CAMP4 Therapeutics Corporation - Common Stock (CAMP) traded between $2.90 and $7.75 over the past 52 weeks and last traded at $4.33, 44.1% below its 52-week high. Over the past week it ranged between $3.54 and $4.97.

Past 12 Months

+15.8%

+18.3%

+3.8%

-3.8%

-27.8%

+4.1%

1W +$0.59

1M +$0.67

3M +$0.16

6M -$0.17

YTD -$1.67

1Y +$0.17

CAMP was +4.1% over the past year, -3.8% over six months, -27.8% year to date, +15.8% in the last week.

12 Months vs Market

CAMP

+4.1%

DIA

+10.1%

SPY

+10.0%

QQQ

+8.3%

IWM

+15.0%

Over the past 12 months CAMP returned +4.1% versus DIA (Dow) +10.1%, SPY (S&P 500) +10.0%, QQQ (Nasdaq 100) +8.3% and IWM (Russell 2000) +15.0%.

Volume & Liquidity

185.9K

142.4K

256.5K

233.6K

YTD

202.0K

202.6K

CAMP's 3-month average daily volume is 256.5K.

More News

CAMP4 Reports Third Quarter 2026 Financial Results and Corporate Highlights

November 05, 2026

CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union

October 27, 2026

CAMP4 Conference: Korro, Tevard Spotlight RNA Fixes for Genetic Disease ↗

October 20, 2026

CAMP4 to Participate in Chardan’s 10th Annual Healthcare Conference

October 14, 2026

CAMP4 Targets Q4 ASCEND Trial Start for SYNGAP1 Therapy CMP-002 ↗

September 28, 2026

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

September 10, 2026

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

September 08, 2026

CAMP4 to Participate in Upcoming Investor Conferences

September 01, 2026

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 13, 2026

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

August 04, 2026

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

July 27, 2026

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 17, 2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 19, 2026

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer ↗

May 31, 2026

Via The Motley Fool

CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 21, 2026

CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder

May 14, 2026

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

May 07, 2026

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

April 28, 2026

CAMP4 Appoints Michael MacLean to its Board of Directors

March 24, 2026

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗

March 18, 2026

Via The Motley Fool

Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit ↗

March 18, 2026

Via The Motley Fool

CAMP4 to Participate in Upcoming Investor Conferences

March 06, 2026

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

March 05, 2026